These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9923826)

  • 41. [A second allogeneic transplantation with a mild conditioning regimen in a patient with a posttransplantation relapse of lymphoblastic lymphoma after achieving aplasia with Daunoxome and alkeran].
    Obukhova EE; Melkova KN; Tugova SV; Konchalovskiĭ MV; Baranov AE
    Ter Arkh; 2000; 72(7):68-9. PubMed ID: 10983327
    [No Abstract]   [Full Text] [Related]  

  • 42. Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma.
    Ferrandina G; Lorusso D; Longo R; Testa AC; Scambia G
    Gynecol Oncol; 2005 Aug; 98(2):332-3. PubMed ID: 15907985
    [No Abstract]   [Full Text] [Related]  

  • 43. Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain.
    Peng H; Du D; Zhang J
    Ther Deliv; 2013 Dec; 4(12):1475-7. PubMed ID: 24304243
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
    Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
    Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
    [No Abstract]   [Full Text] [Related]  

  • 45. Release of daunorubicin from polymethylmethacrylate for the improvement of the local growth control of bone metastasis animal experiments.
    Fröschle GW; Mählitz J; Langendorff HU; Achilles E; Pollock J; Jungbluth KH
    Anticancer Res; 1997; 17(2A):995-1002. PubMed ID: 9137440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
    Creutzig U; Körholz D; Niemeyer CM; Kabisch H; Graf N; Reiter A; Scheel-Walter H; Bender-Götze C; Behnisch W; Hermann J; Mann G; Ritter J; Zimmermann M
    Klin Padiatr; 2000; 212(4):163-8. PubMed ID: 10994544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A pilot study of combined chemotherapy using methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) for advanced or recurrent gastric cancer].
    Yamamura Y; Kodera Y; Kito T
    Gan To Kagaku Ryoho; 1995 Sep; 22(10):1407-10. PubMed ID: 7668879
    [No Abstract]   [Full Text] [Related]  

  • 48. Liposomal doxorubicin.
    Wilkinson K
    Clin J Oncol Nurs; 2002; 6(1):59-61. PubMed ID: 11842492
    [No Abstract]   [Full Text] [Related]  

  • 49. Intravesical idarubicin: a dose-finding study.
    Boccardo F; Cannata D; Cussotto M; Schenone M; Curotto A
    Cancer Chemother Pharmacol; 1996; 38(1):102-5. PubMed ID: 8603442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A case of recurrent malignant glioma treated by superselective intraarterial chemotherapy with a combination of etoposide and cisplatin].
    Nakagawa H; Kubo S; Fujita T; Tsuruzono K; Miyawaki Y; Arita N; Hayakawa T
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):237-40. PubMed ID: 1736836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immobilized forms of daunorubicin in patients with acute leukemia].
    Isaev VG; Garmaeva TTs; Skorokhod AA; Parovichnikova EN; Tiurina NG; Kucher RA; Vitvitskiĭ VM; Ataullakhanov FI; Savchenko VG
    Ter Arkh; 1999; 71(10):32-7. PubMed ID: 10612171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the cardiovascular actions of daunomycin, adriamycin and N-acetyldaunomycin in hamsters and monkeys.
    Herman E; Mhatre R; Lee IP; Vick J; Waravdekar VS
    Pharmacology; 1971; 6(4):230-41. PubMed ID: 5002849
    [No Abstract]   [Full Text] [Related]  

  • 53. Liposomal anthracyclines for brain tumors.
    Mantadakis E; Kamen B
    Pediatr Hematol Oncol; 1999; 16(2):89-91. PubMed ID: 10100267
    [No Abstract]   [Full Text] [Related]  

  • 54. Daunorubicin cardiotoxicity in childhood cancer.
    Samuel L; Cummings J; Shaw P
    Lancet; 1998 Oct; 352(9134):1150. PubMed ID: 9798620
    [No Abstract]   [Full Text] [Related]  

  • 55. Local and systemic sequelae of mediastinal daunorubicin extravasation in a patient with acute myelomonocytic leukemia.
    Dührsen U; Heinrichs V; Beecken WD; Herbst K; Mross K; Hossfeld DK
    Ann Oncol; 1997 Nov; 8(11):1167-8. PubMed ID: 9426340
    [No Abstract]   [Full Text] [Related]  

  • 56. Cyclophosphamide versus ifosfamide in paediatric oncology.
    Chastagner P; Sommelet-Olive D
    Lancet; 1990 Oct; 336(8722):1067-8. PubMed ID: 1977038
    [No Abstract]   [Full Text] [Related]  

  • 57. [Recurrent tumors in an angiogram].
    GLONING K
    Acta Neurochir Suppl (Wien); 1955; 3():250-60. PubMed ID: 13301557
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.
    Jennings MT; Iyengar S
    CNS Drugs; 2001; 15(9):719-43. PubMed ID: 11580310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors.
    Boiardi A; Pozzi A; Salmaggi A; Eoli M; Zucchetti M; Silvani A
    Cancer Chemother Pharmacol; 1999; 43(2):178-9. PubMed ID: 9923826
    [No Abstract]   [Full Text] [Related]  

  • 60. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors.
    Lippens RJ
    Pediatr Hematol Oncol; 1999; 16(2):131-9. PubMed ID: 10100273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.